RAS status in ctDNA and efficacy of FOLFIRI plus ramucirumab in 2nd-line therapy for RAS wild-type mCRC: JACCRO CC-16ARYu Sunakawa,Hisateru Yasui,Masato Matsuura,Takashi Mine,Yasuhiro Yuasa,Takanori Watanabe,Tatsuya Kinjo,Yoshihiro Okita,Hiroyuki Okuyama,Satoshi Yuki, Koki Miyakawa, Ayana Kobara,Wataru Ichikawa,Masashi Fujii,Akihito TsujiANNALS OF ONCOLOGY（2023）引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
